西格列汀联合唑来膦酸与二甲双胍治疗2型糖尿病合并骨质疏松症对患者骨代谢及胰岛素抵抗的影响
Effects of Sitagliptin combined with Zoledronic Acid and Metformin on Bone Metabolism and Insulin Resistance in Patients with Type 2 Diabetes Mellitus complicated with Osteoporosis
张艺露 1白雪剑 2高九青3
作者信息
- 1. 辽宁健康产业集团阜新矿总医院全科医学科,辽宁阜新 123000
- 2. 辽宁健康产业集团阜新矿总医院骨科,辽宁阜新 123000
- 3. 辽宁健康产业集团阜新矿总医院内分泌科,辽宁阜新 123000
- 折叠
摘要
目的 探讨西格列汀联合唑来膦酸、二甲双胍治疗2 型糖尿病合并骨质疏松症对患者骨代谢及胰岛素抵抗的影响.方法 选取 2020 年 3 月至 2021 年 3 月辽宁健康产业集团阜新矿总医院收治的 120 例 2 型糖尿病合并骨质疏松症患者作为研究对象,根据信封法随机分为观察组(61 例)和对照组(59 例).对照组口服二甲双胍联合唑来膦酸治疗,观察组口服西格列汀联合唑来膦酸、二甲双胍治疗.比较两组患者治疗效果,治疗前后体重指数、血糖指标、骨代谢水平、胰岛素抵抗情况.结果 观察组治疗有效率96.72%显著高于对照组的84.75%,差异有统计学意义(P＜0.05).治疗前两组体重指数、空腹血糖、糖化血红蛋白、碱性磷酸酶、骨钙素、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)比较,差异无统计学意义(P＞0.05);治疗后两组体重指数、空腹血糖、糖化血红蛋白、碱性磷酸酶较治疗前降低,且观察组低于对照组,两组骨钙素较治疗前升高,且观察组高于对照组,差异有统计学意义(P＜0.05);治疗后,观察组 HOMA-IR低于对照组,HOMA-β高于对照组,差异有统计学意义(P＜0.05).结论 西格列汀联合唑来膦酸、二甲双胍治疗 2 型糖尿病合并骨质疏松症,可有效改善患者骨代谢水平,同时抑制机体胰岛素抵抗.
Abstract
Objective To explore the effects of sitagliptin combined with Zoledronic acid and metformin on bone metabolism and insulin resistance in patients with type 2 diabetes mellitus complicated with osteoporosis.Methods A total of 120 patients with type 2 diabetes mellitus combined with osteoporosis admitted to Fuxin Mine General Hospital of Liaoning Health Industry Group from March 2020 to March 2021 were selected as the study objects,and were randomly divided into observation group(61 cases)and control group(59 cases)according to envelope method.The control group was treated with metformin combined with zoledronic acid,and the observation group was treated with sitagliptin combined with zoledronic acid and metformin.The therapeutic effect,body mass index,blood glucose index,bone metabolism level and insulin resistance of the two groups before and after treatment were compared.Results The effective rate of treatment in observation group was 96.72%,which was significantly higher than that in control group(84.75%),and the difference was statistically significant(P＜0.05).Before treatment,there were no significant differences in body mass index,fasting blood glucose,glycated hemoglobin,alkaline phosphatase,osteocalcin,insulin resistance index(HOMA-IR)and islet beta cell function index(HOMA-β)between the two groups(P＞0.05).After treatment,body mass index,fasting blood glucose,glycated hemoglobin and alkaline phosphatase in both groups were lower than before treatment,and the observation group was lower than the control group,osteocalcin in both groups was higher than before treatment,and the observation group was higher than the control group,the difference was statistically significant(P＜0.05);After treatment,HOMA-IR in observation group was lower than control group,HOMA-β was higher than control group,the difference was statistically significant(P＜0.05).Conclusion Sitagliptin combined with Zoledronic acid and metformin can effectively improve bone metabolism and inhibit insulin resistance in patients with type 2 diabetes mellitus combined with osteoporosis.
关键词
西格列汀/唑来膦酸/二甲双胍/2型糖尿病/骨质疏松症/治疗效果/糖化血红蛋白/空腹血糖/碱性磷酸酶/骨钙素Key words
Sitagliptin/Zoledronic acid/Metformin/Type 2 diabetes combined/Osteoporosis/Treatment effect/Glycated A 1 c/Fasting blood glucose/Alkaline phosphatase/Osteocalcin引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据